دورية أكاديمية
I Seed Permanent Implantation as a Palliative Treatment for Stage III and IV Hypopharyngeal Carcinoma
| العنوان: | I Seed Permanent Implantation as a Palliative Treatment for Stage III and IV Hypopharyngeal Carcinoma |
|---|---|
| المؤلفون: | Lei Li, Jie Yang, Xiaojiang Li, Xiaoli Wang, Yanxin Ren, Jimin Fei, Yan Xi, Ruimei Sun, Jing Ma |
| المصدر: | Clinical and Experimental Otorhinolaryngology, Vol 9, Iss 3, Pp 185-191 (2016) |
| بيانات النشر: | Korean Society of Otorhinolaryngology-Head and Neck Surgery, 2016. |
| سنة النشر: | 2016 |
| المجموعة: | LCC:Medicine LCC:Otorhinolaryngology |
| مصطلحات موضوعية: | Hypopharyngeal Neoplasms, Brachytherapy, Palliative Care, Medicine, Otorhinolaryngology, RF1-547 |
| الوصف: | Objectives. The aim of this study was to investigate the feasibility and safety of percutaneous 125I seed permanent implantation for advanced hypopharyngeal carcinoma from toxicity, tumor response, and short-term outcome. Methods. 125I seeds implant procedures were performed under computed tomography for 34 patients with advanced hypopharyngeal carcinoma. We observed the local control rate, overall survival, and acute or late toxicity rate. Results. In the 34 patients (stage III, n=6; stage IV, n=28), the sites of origin were pyriform sinus (n=29) and postcricoid area (n=5). All patients also received one to four cycles of chemotherapy after seed implantation. The post-plan showed that the actuarial D90 of 125I seeds ranged from 90 to 158 Gy (median, 127 Gy). The mean follow-up was 12.3 months (range, 3.4 to 43.2 months). The local control was 2.1–31.0 months with a median of 17.7 months (95% confidence interval [CI], 13.4 to 22.0 months). The 1-, 2-, and 3-year local controls were 65.3%, 28.6%, and 9.5% respectively. Twelve patients (35%) died of local recurrence, fourteen patients (41%) died of distant metastases, and three patients (9%) died of recurrence and metastases at the same time. Five patients (15%) still survived to follow-up. At the time of analysis, the median survival time was 12.5 months (95% CI, 9.5 to 15.4 months). The 1-, 2-, and 3-year overall survival rates were 55.2%, 20.3%, and 10.9%, respectively. Five patients (15%) experienced grade 3 toxic events and nine patients (26%) have experienced grade 2 toxic events. Conclusion. This review shows relatively low toxicity for interstitial 125I seed implantation in the patients with advanced stage hypopharyngeal cancer. The high local control results suggest that 125I seed brachytherapy implant as a salvage or palliative treatment for advanced hypopharyngeal carcinoma merit further investigation. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1976-8710 2005-0720 |
| Relation: | http://www.e-ceo.org/upload/pdf/ceo-2015-00213.pdf; https://doaj.org/toc/1976-8710; https://doaj.org/toc/2005-0720 |
| DOI: | 10.21053/ceo.2015.00213 |
| URL الوصول: | https://doaj.org/article/84965e8ddcf4461dad65f669a1515d11 |
| رقم الأكسشن: | edsdoj.84965e8ddcf4461dad65f669a1515d11 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 19768710 20050720 |
|---|---|
| DOI: | 10.21053/ceo.2015.00213 |